Clinical Trials

Trial Name	Description
ORZORA GYN	Dr. S Welch An Open-Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness ans Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients who are in Complete or Partial Respons
R2810-ONC-1676	Dr. Stephen Welch An Open-Label, Randomized, Phase 3 Clinical Trial of REGN2810 Versus Therapy of Investigator's Choice Chemotherapy in Recurrent or Metastatic Platinum-Refractory Cervical Carcinoma.
CXMET	Dr. David D'Souza The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial.
CX.5 SHAPE GYN	Dr. Prefontaine A Randomized Phase III Trial Comparing Radical Hysterectomy And Pelvic Node Dissection vs. Simple Hysterectomy And Pelvic Node Dissection in Patients With Low-Risk Early-Stage Cervical Cancer
Keynote 775 GYN	Dr. S. Welch A multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination with Pembrolizumab versus Treatment of Physician's Choice in Participants with Advanced Endometrial Cancer
PRIMA GYN	Dr. S. Welch A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients with HRD-Positive Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy
Ariel 4 GYN	Dr. S. Welch A Phase 3 Multicenter, Randomized Study of Rucaparib versus Chemotherapy in Patients with Relapsed, BRCA-Mutant, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
FORWARD 1 GYN	Dr. S. Welch A Randomized, Open Label Phase 3 Study to Evaluate the Safety and Efficacy of Mirvetuximab Soravtansine (IMGN853) versus Investigator's Choice of Chemotherapy in Women with Folate Receptor positive Advanced Epithelial Ovarian Cancer, Primar
OVC.2 GYN	Dr. Stephen Welch "not yet open" A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or pr
C31004 GYN	Dr. S. Welch A Phase 2, Randomized Study of MLN0128 (a Dual TORC1/2 inhibitor), MLN0128 + MLN1117 (a PI3K Inhibitor), Weekly Paclitaxel, or the Combination of Weekly Paclitaxel and MLN0128 in Women with Advanced, Recurrent, or Persistent Endometrial Can
FIRST	Dr. Stephen Welch "not yet open" A Randomized, Double-Blind, Phase 3 Comparison of Platinum-Based Therapy With TSR-042 and Niraparib Versus Standard of Care Platinum-Based Therapy as First-Line Treatment of Stage II or IV Nonmucinous Epithelial Ovarian Cancer.